It would be highly interesting to investigate whether those with glial tumors where the cells having OPC identities constitute the majority of the tumor mass, such as proneural subtype of GBM, oligodendrogliomas, and DIPGs, would particularly benefit from IGF1R targeted therapy. The gene discussed is IGF1R; the disease is oligodendroglioma.